Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Innovative Research Reagents for Inflammation & Immune Responses
Toggle Nav
New Products Archive |
|
Latest Product Highlights ArchiveNew Long-Lasting Human IL-35 InVivoKine™
|
News & Press ReleasesAbcalis and AdipoGen Life Sciences Partner on Distributing Animal-free Recombinant Monoclonal and Multiclonal Antibodies on the Life Science Research Market LRIG1 is a New Inhibitory Immune Checkpoint Protein that acts as a VISTA-binding Partner A recent study in Science Immunology identifies LRIG1 as a new VISTA binding partner that works at acidic and neutral pH. LRIG1 is as an inhibitory receptor that, via VISTA, controls antitumor immunity by impairing the expansion, survival, and effector function of tumor-specific CD8+ cytotoxic T cells. VISTA/LRIG1 signaling may be an effective immunotherapeutic approach for the treatment of cancer. |
Collaborating with |
|